Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08 Noviembre 2024 - 3:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 8, 2024
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Novo Nordisk A/S – Share repurchase
programme
Bagsværd, Denmark, 8 November 2024 – The execution
of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S
has now initiated a new share repurchase programme of up to DKK 3,136,206,122.30 in accordance with Article 5 of Regulation No 596/2014
of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016
(the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and
to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period
starting 11 November 2024 and ending on 3 February 2025. A maximum of 400,000,000 B shares of DKK 0.10 in total can be bought during the
trading period.
Novo Nordisk is a leading global healthcare
company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon
our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent
and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
|
|
|
Investors: |
|
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
|
|
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com |
|
|
|
|
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com |
|
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com CVR no: 24 25 67 90 |
| | | Company
announcement No 85 / 2024 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 8, 2024 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Novo Nordisk (NYSE:NVO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024